Quantcast

Metformin, naltrexone, or the combination of prednisolone and antiandrogenic oral contraceptives as first-line therapy in hyperinsulinemic women with polycystic ovary syndrome.

Research paper by Dijana D Hadžiomerović-Pekić, Ludwig L Wildt, Jürgen Michael JM Weiss, Kay K Moeller, Verena V Mattle, Beata E BE Seeber

Indexed on: 02 Apr '10Published on: 02 Apr '10Published in: Fertility and Sterility®



Abstract

To compare the short-term effects of metformin (M), naltrexone (N), and a combination of OC and prednisolone (OC/Pr) on the metabolic state and the ovarian function of PCOS women, we randomized 29 women to a 3-month course of therapy. We observed significant improvements in hyperandrogenemia and ovulation rates in PCOS women of all three groups, in the absence of changes in the metabolic state, suggesting that insulin resistance in PCOS patients is only one of several factors leading to hyperandrogenemic ovarian failure.